Show simple item record

dc.contributor.authorMeek, Claireen
dc.contributor.authorLewis, Hannah Ben
dc.contributor.authorReimann, Franken
dc.contributor.authorGribble, Fionaen
dc.contributor.authorPark, Adrian Jen
dc.date.accessioned2015-09-29T13:01:18Z
dc.date.available2015-09-29T13:01:18Z
dc.date.issued2015-09-05en
dc.identifier.citationMeek et al. Peptides (2015) Vol. 77, pp. 28-37. doi:10.1016/j.peptides.2015.08.013en
dc.identifier.issn0196-9781
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/251213
dc.description.abstractBariatric surgery for obesity has proved to be an extremely effective method of promoting long-term weight reduction with additional beneficial metabolic effects, such as improved glucose tolerance and remission of type 2 diabetes. A range of bariatric procedures are in common use, including gastric banding, sleeve gastrectomy and the Roux-en-Y gastric bypass. Although the mechanisms underlying the efficacy of bariatric surgery are unclear, gastrointestinal and pancreatic peptides are thought to play an important role. The aim of this review is to summarise the effects of different bariatric surgery procedures upon gastrointestinal and pancreatic peptides, including ghrelin, gastrin, cholecystokinin (CCK), glucose-dependent insulinotropic hormone (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), oxyntomodulin, insulin, glucagon and somatostatin.
dc.description.sponsorshipResearch in the F. Reimann and F.M. Gribble laboratories is funded by the Wellcome Trust (WT084210Z/07/Z and WT088357Z/09/Z), the MRC (MRC_MC_UU_12012/3) and Full4Health (FP7/2011-2015, grant agreement no. 266408). Claire Meek receives additional salary funding from the Wellcome Trust Translational Medicine and Therapeutics Programme, funded by the Wellcome Trust in association with Glaxo SmithKline.
dc.languageEnglishen
dc.language.isoenen
dc.publisherElsevier
dc.rightsCreative Commons Attribution 4.0
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBariatricen
dc.subjectGhrelinen
dc.subjectGastrinen
dc.subjectCholecystokininen
dc.subjectIncretinen
dc.subjectOxyntomodulinen
dc.titleThe effect of bariatric surgery on gastrointestinal and pancreatic peptide hormonesen
dc.typeArticle
dc.description.versionThis is the final version of the article. It first appeared from Elsevier via http://dx.doi.org/10.1016/j.peptides.2015.08.013en
prism.endingPage37
prism.publicationDate2015en
prism.publicationNamePeptidesen
prism.startingPage28
prism.volume77en
dc.rioxxterms.funderWellcome Trust
dc.rioxxterms.funderMRC
dc.rioxxterms.projectidWT084210Z/07/Z
dc.rioxxterms.projectidWT088357Z/09/Z
dc.rioxxterms.projectidMRC_MC_UU_12012/3
dcterms.dateAccepted2015-08-19en
rioxxterms.versionofrecord10.1016/j.peptides.2015.08.013en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2015-09-05en
dc.contributor.orcidMeek, Claire [0000-0002-4176-8329]
dc.contributor.orcidReimann, Frank [0000-0001-9399-6377]
dc.contributor.orcidGribble, Fiona [0000-0002-4232-2898]
dc.identifier.eissn1873-5169
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (MC_UU_12012/3)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0
Except where otherwise noted, this item's licence is described as Creative Commons Attribution 4.0